Loading clinical trials...

Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response | Clinical Trials | Clareo Health

UNKNOWNPHASE4

Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response

NCT01530711•Pere Gines

View on ClinicalTrials.gov

Summary

Observe the effect of terlipressin on renal function in patients with SHR type I adjusting the dose based on hemodynamic response.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with hepatorenal syndrome type 1.
•Signed informed consent.

Exclusion Criteria

•At least 18 years old
•Negative pregnancy test in serum or urine in women of childbearing age, and agree to use adequate contraception since at least 14 days prior to the first dose of study drug until 14 days after the last.
•Hepatocellular carcinoma: exclusion of patients with hepatocellular carcinoma who present more than 3 nodules, single nodule larger than 5 cm, tumor portal thrombosis or extrahepatic tumor spread.
•Active bacterial infection with symptoms of systemic inflammatory response (fever, tachycardia, tachypnea, hypotension, septic or blood count).
•Cardiac or respiratory failure clinically significant.
•Clinically significant peripheral artery disease.
•A history of ischemic heart disease.
•Hypersensitivity to terlipressin and / or albumin or any of the excipients.
•Pregnancy.
•Septic shock.
+2 more criteria

Locations (6)

Hospital Clinic i Provincial de Barcelona

Barcelona, Barcelona, Spain

Hospital del Mar

Barcelona, Barcelona, Spain

Hospital Vall d´Hebron

Barcelona, Barcelona, Spain

Hospital de la Santa Creu i Sant Pau

Barcelona, Barcelona, Spain

Corporació Sanitària Parc Taulí

Sabadell, Barcelona, Spain

Hospital Moisés Broggi

Sant Joan Despí, Barcelona, Spain

Key Dates

Start Date

April 1, 2012

Primary Completion Date

December 1, 2016

Completion Date

December 1, 2016

Last Updated

August 18, 2016

Enrollment

ESTIMATED participants

Conditions

CirrhosisHepatorenal Syndrome Type I

Interventions

Terlipressin and albumin

DRUG

EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.

NCT05597488

Cirrhosis Portal

View study

RECRUITINGNA

Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis

NCT06932783

Cirrhosis

View study

RECRUITING

Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 18, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treatment of Hepatorenal Syndrome With Terlipressin Infusion Adjusted to Hemodynamic Response

Inclusion Criteria

Exclusion Criteria

EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.

Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis

Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias

Mechanism of TIPS to Improve Sarcopenia

Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care

Verification of Risk Factors of Thrombohemorrhagic Complications in Recipients After Related Liver Transplantation